Research progress on photodynamic therapy combined with PD-1/PD-L1 inhibitors in anti-tumor therapy

Abstract

Photodynamic therapy has become one of the important options for adjuvant therapy of various tumors. In recent years， monoclonal antibodies targeting immune checkpoints have shown the clinical promise in a range of cancers. Treatment regimens that combine photodynamic therapy with immune checkpoint inhibitors help to amplify therapeutic effects and minimize side effects， and have shown preliminary combined anti-tumor efficacy in animal and human studies. In this article， the anti-tumor effect， as well as the immunological changes after the combined treatment with photodynamic therapy and immune checkpoint inhibitors in breast cancer， colorectal cancer， renal cell carcinoma， malignant melanoma and other malignant tumors were reviewed， aiming to provide a theoretical basis for the optimization of anti-tumor combination therapy.

Keywords

• |photodynamic therapy|immune checkpoint inhibitor|programmed cell death-1 / programmed cell death-ligand1|combination therapy|tumor